Incidence rates2 | Temporal trends | ||||
---|---|---|---|---|---|
Diagnostic group1 | Cases ( N) | Rate | (95% CI) | AAPC | P-value |
Leukaemia | 1299 | 17 | (16–19) | 0.12% | 0.901 |
ALL | 591 | 6 | (6–7) | 1.20% | 0.401 |
AML | 463 | 7 | (6–8) | −1.47% | 0.357 |
CML | 147 | 2 | (1–2) | 4.98% | 0.091 |
Other Leukaemia | 98 | 1 | (1–2) | −5.71% | 0.095 |
Lymphoma | 3070 | 45 | (43–48) | 1.17% | 0.063 |
Hodgkin Lymphoma | 2079 | 33 | (31–35) | 1.96% | 0.078 |
Non-Hodgkin Lymphoma | 991 | 12 | (11–13) | 0.79% | 0.297 |
CNS Tumours | 1882 | 29 | (27–31) | 0.37% | 0.644 |
Astrocytoma | 629 | 9 | (8–10) | −0.58% | 0.674 |
Other Gliomas | 195 | 3 | (2–3) | 2.23% | 0.374 |
Ependymoma | 99 | 2 | (1–2) | 3.53% | 0.321 |
Medulloblastoma | 111 | 2 | (1–2) | −2.68% | 0.406 |
Other CNS | 702 | 12 | (11–14) | −0.50% | 0.702 |
Unspecified CNS | 2 | (2–3) | 6.82% | 0.023 | |
Leukaemia, Lymphoma, CNS tumours | 6251 | 92 | (89–96) | 0.71% | 0.106 |